Jim Tananbaum Led a Funding Series for a Healthcare Startup

Mindstrong recently raised $14 million in a Series A funding. The Neurological solutions start-up said that the money would be used to enhance the diagnosis and neuropsychiatric treatment system. This funding initiative was led by Foresite Capital and ARCH Venture Partners. Other investors who participated include Optum Ventures, One Mind Brain Health Impact Fund, and Berggruen Holdings.

The AI-powered platform uses patient’s smartphone user habits such as typing and scrolling patterns to offer a better measurement of brain activity. The platform will provide information about the patient’s mood and the brain’s processing speed, function, and memory. Paul Dagum is the CEO of Mindstong. He spoke during a press briefing and pointed out that tracking of mental health is still based on clinical reports despite the fact that modern medicine is based on accurate measurements. The startup will now offer an improved and objective diagnosis of mental disorders as a result of the new investment. These sentiments were echoed by Dr. Tom Insel who is the president and co-founder of Mindstong Health. Tom further pointed out that the new diagnosis approach will serve as the impetus for developing better mental health care interventions.

According to INC42, Jim Tananbaum is the CEO of Foresite Capital. He said that Mindstrong Health founding members bring unique experience, skills, and technical vision on board. The team understands the shortcoming with regards to caring for patients with mental disorders. A combination of Tom, Rick, and Paul put Mindstong Health in a better position to develop better and modernized ways of providing care.

Jim Tananbaum has a wealth of experience in healthcare investments. He has led more than 21 successful investments in various healthcare companies including Jazz Pharmaceutical, Amerigroup, and Amira Pharmaceutical. Jim held several high-level positions at various venture enterprises that focused on healthcare sector including Sierra Ventures, Theravance, and Prospect Venture Partners before this role. Visit Ideamensch for more info.

Dr. Tananbaum holds a BS and B.S.E.E from Yale University and an M.D from Harvard University. Jim also has an MBA from Harvard Business School and a Masters of Science from Massachusetts Institute of Technology. Jim has served on advisory boards of both Yale University (School of Engineering) and Harvard-MIT HST program.

See more: https://www.researchgate.net/profile/Jim_Tananbaum

Jeanmarie Guenot; CEO And President Of Amphivena

 

Jeanmarie Guenot has built a remarkable career. She has worked in both the private and public sectors that have contributed to her success.

 

 

Jeanmarie Guenot is the current CEO and President of the Amphivena therapeutics company. This is a company that is focused on developing innovative for bifunctional antibody therapies.

Newson6 covered Jeanmarie’s most recent initiative to research T-cells for cancer therapy and treatment.

 

Prior to joining the company, she founded the SKS Ocular Company in 2009. She also served as the first employee of the company. This is a start up an ophthalmic facility that is focused on dry AMD. She was with the company for3 years before leaving.

 

 

Jeanmarie Guenot was also the business advisor for the Hoffman-la rochie. This was her first job that set her through the path of success. In her career, she worked as the managing director of the Guenot Company. She, however, held the position for one year. Between 2003 and 2008 she was the vice president and head of the corporate and business development of the PDL BioPharma. She was also the associate of the Atlas venture for three years.

 

 

She earned her MBA from the University of Pennsylvania at the Wharton School and also Ph.D. from the University of California.  Further background on Dr. Guenot can be sought on LinkedIn here: https://www.linkedin.com/in/jeanmarie-guenot-4a140617

 

 

About Amphivena therapeutics

 

 

This is a company that is focused on developing antibody therapy to deal with blood cancer. The mission of the company is to participate in research projects that will help in the eradication of cancer. They are looking to enhance the patients’ immunity which will eventually help in destroying the cancer cells. They have a team that is focused on restoring the blood formation and circulation.

 

 

It is their partnerships that have helped them in achieving their success. They have combined their expertise, resources, and strengths in developing the innovative therapies for the patients.

 

 

The most interesting fact about this company is that it is managed by a team of successful women. In addition to Jeanmarie, there are other experienced and knowledgeable women who have gained skills in the pharmaceutical industry. The team includes; Lori Kunkel, Judith A Fox, Jennifer Sims and Susan Dana Jones.  Recently, Jeanmarie entered a partnership with Takeda, through Amphivena, to further biotechnological research.

Reviewing The Contribution Of Penelope Kokkinides And Rick Shinto To InnovaCare Health

Healthcare provision in many countries is solely handled by the government and very few organs are left in the hands of the private companies on Yahoo. However, this may not be the best idea since the desired quality of care may not be handled by the government. The private healthcare industry has grown over the years with the introduction of new firms and new methods of dealing with problems. When the government introduce Medicare Advantage on innovacarewellness.com, it opened new doors for private companies to venture into the field. Many companies that have invested in the area well are today established and performing well due to the huge number of clients served.

InnovaCare Health enjoys great support from users due to the high quality services the company offers. Incepted over 10years ago, InnovaCare Health went through a series of changes in leadership before the company landed in the hands of Rick Shinto, the CEO and President. Good leadership and insightful control has allowed InnovaCare Health to claim a bigger share of the market in the last five years.

About Rick Shinto and Penelope Kokkinides
InnovaCare Health has been built by many professionals, but the effort that Penelope Kokkinides and Rick Shinto put to developing the company cannot be overlooked. Rick Shinto is a graduate of medicine from the State University of Arizona. He also holds an MBA from Redlands University and with his experience of over 20 years, he managed to author journals and articles on danielstraus.org supporting the development of unique and high quality healthcare systems.

He has been working on building InnovaCare Health since he joined the company to serve as the President and CEO in 2012. Rick Shinto enjoys the support and guidance of Penelope Kokkinides and the duo previously worked together at Aveta Inc from 2008 to 2012. When they joined InnovaCare Health, they brought new energy and insight that has been steering the company to rank among the most established in the region.

InnovaCare Health
InnovaCare Health is a managed healthcare provider that serves the Puerto Rico. It currently stands among the best in the country and has managed to come up with new methods of tackling problems. InnovaCare Health works with established professionals who offer insight into the problems the company faces. It is an established provider of Medicare Advantage plans with more than 200,000 users across North America. Most importantly, InnovaCare Health has been working on building a network that allows all clients to access easy support and better services.